Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Humana: Strong Start, Weak Stars— But a $9B CMS Clawback Overhang Puts Balance Sheet Agility to the Test!
Humana’s Q1FY25 print showed disciplined execution with EPS ahead of expectations, though driven by expense timing, not core upside; FY EPS guide ($16.25) and Insurance Segment Benefit Ratio (90.1%-90.5%) were reaffirmed. MA membership dynamics remain on track, with margin uplift from strategic duals exit and favorable mix shift. CenterWell contributed meaningfully (1/3 of EPS upside), with strong PCO growth and Specialty Pharmacy mix, while Medicaid added 100K members YTD and offers expanding diversification. Stars recovery efforts (25% YoY care gap closure, 30–50% better refill rates) are progressing, supporting the 3% MA margin target by 2027. AI-driven G&A efficiencies are emerging, though the external regulatory backdrop now dominates risk. CMS’s May 21 announcement of potential retrospective MA clawbacks ($9B exposure for HUM) adds material balance sheet uncertainty, compounding existing Stars and IRA-driven pressures. Management remains transparent on Stars litigation timing and reiterated no impairment to CenterWell profitability. While Medicaid scaling and MA mix upgrades offer long-term tailwinds, regulatory and cash flow risks cloud near-term valuation clarity. Execution on controllable levers is strong, but clawback overhang materially raises downside skew. Can Humana maintain balance sheet flexibility and margin trajectory while navigating the dual challenge of regulatory headwinds and volatile Stars-linked earnings visibility?
